 |
News
-
ANAFAM, the National Association of Medicines Manufacturers of Mexico, joins IGBA (September 2023)
IGBA, the International Generic and Biosimilar medicines Association, representing global manufacturers of generic and biosimilar medicines, announced today that ANAFAM has been accepted and welcomed as a new IGBA Associate Member.
Read More -
Global regulators and biopharmaceutical and vaccine industry to share experiences with managing pharmaceutical quality systems (July 2023)
On 20 July 2023, the International Coalition of Medicines Regulatory Authorities (ICMRA) is hosting a virtual workshop on the development of a global Pharmaceutical Quality Knowledge Management System (PQ KMS), which aims to facilitate the exchange of knowledge related to
… Read More -
IGBA Welcomes ICH New Topic for Harmonisation: “Bioequivalence for Modified-Release Products” (June 2023)
The International Generic and Biosimilar Medicines Association ( IGBA ) commends the General Assembly of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use ( ICH ) for its adoption of a new topic focused on the harmonisation of " Bioequivalence
… Read More -
IGBA CEO Advisory Committee Vienna Statement - Four Keys to More Predictable Supply Chains (June 2023)
Vienna, June 14, 2023 - The COVID-19 pandemic demonstrated the critical importance of resilient global supply chains. As the CEO Advisory Committee of the International Generic and Biosimilar Medicines Association (IGBA), we underscore the essential role of the off-patent pharmaceutical sector
… Read More -
IGBA detailed comments and proposals on the Pandemic Accord (Zero Draft - May 2023)
IGBA is pleased to share key comments and proposals on selected provisions of the Zero Draft of the Pandemic Accord
Read More -
IGBA Perspectives on Pandemic Accord (Zero Draft – April 2023)
The criticality of supply chain resilience has become increasingly apparent in recent years, including for essential medicines and health products. The COVID-19 pandemic and geopolitical tensions have highlighted certain vulnerabilities of global supply chains, particularly in the areas of raw
… Read More -
IGBA nominated David Gaugh, AAM's Interim CEO, as the new IGBA Chair for 2023 (April 2023)
IGBA informs that Jonathan Kimball is no longer part of the staff of the Association for Accessible Medicines (AAM), our U.S. IGBA Member, and hence, is no longer in the position as IGBA Chair. Subsequently, David Gaugh , AAM's Interim CEO,
… Read More -
IGBA’s 25th Annual Conference highlights the true value of the off-patent medicines industry for patients and health systems around the world (February 2023)
IGBA, the International Generic and Biosimilar medicines Association, representing global manufacturers of generic and biosimilar medicines, announced today that experts and leaders from the local and global generic and biosimilar medicines industries, Government and regulatory agencies, academia and other stakeholders
… Read More -
Jonathan Kimball takes over the position of IGBA Chair (January 2023)
The International Generic and Biosimilar Medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announced today that Jonathan Kimball, Vice President of Trade and International Affairs of the Association for Accessible Medicines (AAM), Vice-Chair IGBA and Vice Chair
… Read More -
IGBA taking action to tackle shortages of antibiotic medicines (December 2022)
The global generic medicines industry supplies most of the world’s antibiotic medicine and is aware of the current surge in demand of these products that is leading to shortages. The surge is driven by an unusually high rate of respiratory
… Read More -
IGBA Releases Report on Factors Affecting the Supply of Generic Medicines (December 2022)
The International Generic and Biosimilar medicines Association (IGBA) today released a report identifying key factors affecting the security of the global supply of generic prescription medicines.
Read More -
IGBA introductory statement at the Geneva Trilateral Symposium on The Covid 19 Pandemic: Response, Preparedness, Resilience, convened by WHO, WIPO and WTO (December 2022)
The International Generic and Biosimilar Medicines Association is an international organization of national and regional associations representing manufacturers of generic and biosimilar medicines from around the world. Our industry supplies an estimated 80% of all quality-assured medicines globally and is
… Read More
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
